Donghai Securities released a research report on April 15 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the overall performance is in line with expectations; 2) the development of ultrasound is steady, and the prospects for new endovascular ultrasound products are promising; 3) soft lenses are growing rapidly, and minimally invasive surgery continues to expand; 4) gross margin has increased significantly and profitability has increased. (Mainichi Keizai Shimbun)
东海证券4月15日发布研报称，给予开立医疗（300633.SZ）买入评级。评级理由主要包括：1）业绩总体符合预期；2）超声发展稳健，血管内超声新品前景可期；3）软镜快速增长，微创外科持续拓展；4）毛利率显著提升，盈利能力增强。（每日经济新闻）
Donghai Securities released a research report on April 15 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the overall performance is in line with expectations; 2) the development of ultraso
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.